Business Wire

FL-AERA-TECHNOLOGY

Share
Aera Technology Releases New Capabilities to Accelerate Decision Intelligence Adoption

Gartner Supply Chain Symposium/Xpo™ 2022 Aera Technology today announced from the Gartner® Supply Chain Symposium/Xpo™ 2022, the release of new AI/MLOps and developer capabilities for its Aera Decision Cloud™ platform. To speed and scale decision automation, these enhancements add to the platform’s data science engine and provide advanced features for understanding the relationships and effectiveness of decisions. The innovations also strengthen Aera Decision Cloud’s capabilities for supply chain decision flows.

Aera Decision Cloud is designed to accelerate the adoption of Decision Intelligence — the digitization, augmentation, and automation of decision making. It enables companies to make and execute decisions in real-time to optimize business, financial, and operational performance.

According to Gartner, “by 2025, 95% of decisions that currently use data will be at least partially automated.”* Implementing and scaling automated decision-making across one or multiple business functions is difficult and time-consuming without a purpose-built platform. Aera Decision Cloud was designed from the start to empower users with the advanced technologies and tools, in one platform, to aggregate and integrate data from internal and external systems and sources and build and deploy decision-making models that generate informed, automated recommendations for any business scenario.

Today’s product release provides new features for business users that advance and scale Aera Cognitive Skills™ — the platform’s pre-built set of comprehensive decision-making capabilities for demand forecasting, planning, inventory, logistics, procurement, finance, revenue, and more. The release also delivers enhancements for data engineers, data scientists, and developers that optimize their experience in Aera Developer™ , the platform’s integrated development environment (IDE) for creating and deploying Skills, or modifying any deployed Aera Cognitive Skills.

Product release highlights:

  • Enhancements to Aera Cortex™ , the data science engine inside the Aera Cognitive Operating System™ , to improve the user experience, including:
    • New Aera Notebook : Jupyter Notebook open interface provides the ideal environment to easily integrate data science projects and other custom code using Python and R, into Decision Intelligence flows, right from the Aera Decision Cloud platform.
    • New AutoML : Machine learning options enable development of ML decision models — without requiring expertise in model creation, tuning, and deployment.
    • New Model Performance and Versioning : New enhancements automate monitoring, deployment, and versioning of machine learning models to make it much easier to operationalize ML models and scale across the entire enterprise.
  • Advanced intelligence capabilities to provide a deeper understanding of relationships and effectiveness of decisions, including:
    • New Graph Explorer : Advanced graph capabilities to enable data relationships to be used effectively in the decision-making process.
    • New Confidence Score : Confidence score framework, which learns from past, similar recommendations and outcomes, helps determine the decisions that can be automated.
    • New Action Item Node : Addition of a node within the Aera Developer environment to simplify decision management through the ability to more easily create, update, close, and access recommendations.

“Through Aera Decision Cloud, we are re-inventing decision making and accelerating adoption of Decision Intelligence,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. "Today’s comprehensive release for both business end user and data science teams underscores how we are continually advancing and evolving our platform to enable digital decisions at scale in this increasingly complex business environment.”

To see a demo of Aera Decision Cloud and the new features, visit the Aera team at Booth #325, Gartner Supply Chain Symposium/Xpo™ 2022 .

About the Gartner Supply Chain Symposium/Xpo™

Gartner Supply Chain Symposium/Xpo delivers the must-have insights, strategies and frameworks for CSCOs and supply chain leaders to drive impact within their organizations. Supply chain leaders will gather to gain a strategic view of the trends disrupting their business and the insights and frameworks they can use to prepare for disruption, enable digital transformation and build sustainability as a competitive advantage.

*Gartner, Predicts 2022: Data and Analytics Strategies Build Trust and Accelerate Decision Making,” Jorgen Heizenberg, Lydia Clougherty Jones, Ted Friedman, Andrew White, Saul Judah, Gareth Herschel, Rita Sallam, Ehtisham Zaidi, Svetlana Sicular, December 2021. https://www.gartner.com/document/4008991

GARTNER and SUPPLY CHAIN SYMPOSIUM/XPO ™ are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Aera Technology

Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye